A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity

A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity
复制标题

DOI:
10.1073/pnas.212519099
复制
发表时间:
2002-10-15
影响因子:
11.1
通讯作者:
Kim, SH
Kim, SH
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Bufler, P;Azam, T;Kim, SH

文献摘要

被引文献

相似文献

白细胞介素 - 1F7是在表达序列标签数据库中被发现的,它是与白细胞介素 - 1α/β、白细胞介素 - 1受体拮抗剂和白细胞介素 - 18具有序列同源性的不断扩大的蛋白质家族的成员。在本研究中,通过免疫组织化学染色,白细胞介素 - 1F7定位于人外周单核细胞中,这表明它在免疫调节中起作用。重组人白细胞介素 - 1F7b被证明能与白细胞介素 - 18受体α结合,但不具有白细胞介素 - 18的激动或拮抗功能。通过化学交联,我们观察到,与白细胞介素 - 18不同,白细胞介素 - 1F7b无法募集白细胞介素 - 18受体β链以与白细胞介素 - 18受体α链形成具有功能活性的三元复合物。白细胞介素 - 1F7b与白细胞介素 - 18有两个保守的氨基酸(Glu - 35和Lys - 124),它们参与白细胞介素 - 18与白细胞介素 - 18受体α链以及白细胞介素 - 18结合蛋白(IL - 18BP,一种中和白细胞介素 - 18活性的分泌蛋白)的相互作用。在测试白细胞介素 - 1F7b是否与白细胞介素 - 18BP相互作用时,我们意外地观察到,在人自然杀伤细胞系中,白细胞介素 - 1F7b使白细胞介素 - 18BP抑制白细胞介素 - 18诱导的干扰素γ的能力提高了25 - 30%。这种效应主要在白细胞介素 - 18BP的极限浓度(3.12 - 12.5纳克/毫升)以及白细胞介素 - 1F7b摩尔过量50 - 100倍时观察到。使用分离的人外周血单个核细胞也得到了类似的结果。为了研究这种效应的分子基础,我们进行了白细胞介素 - 1F7b和白细胞介素 - 18BP的结合研究。交联后,在十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳(SDS/PAGE)上观察到由白细胞介素 - 1F7b和白细胞介素 - 18BP组成的高分子量复合物。我们提出,在与白细胞介素 - 18BP结合后,白细胞介素 - 1F7b与白细胞介素 - 18受体β形成复合物,使β链无法与白细胞介素 - 18受体α形成功能性受体复合物,从而抑制白细胞介素 - 18的活性。
IL-1F7 was discovered in expressed sequence tag databases as a member of the increasing family of proteins sharing sequence homology to IL-lalpha/beta, IL-1Ra, and IL-18. In the present study using immunohistochemical staining, IL-1F7 was localized in human peripheral monocytic cells, suggesting its role in immune regulation. Recombinant human IL-1F7b was shown to bind to the IL-18Ralpha but without IL-18 agonistic or antagonistic function. Using chemical cross-linking, we observed that, unlike IL-18, IL-1F7b fails to recruit the IL-18Rbeta chain to form a functionally active, ternary complex with the IL-18Ralpha chain. IL-1F7b shares two conserved amino acids with IL-18 (Glu-35 and Lys-124), which participate in the interaction of IL-18 with the IL-18Ralpha chain as well as the IL-18-binding protein (IL-18BP), a secreted protein that neutralizes IL-18 activity. In testing whether IL-1F7b interacts with IL-18BP, we unexpectedly observed that IL-1F7b enhanced the ability of IL-18BP to inhibit IL-18-induced IFNgamma by 25-30% in a human natural killer cell line. This effect was observed primarily at limiting concentrations of IL-18BP (3.12-12.5 ng/ml) and at a 50- to 100-fold molar excess of IL-1F7b. Similar results were obtained by using isolated human peripheral blood mononuclear cells. To study the molecular basis of this effect we performed binding studies of IL-1F7b and IL-18BP. After cross-linking, a high molecular weight complex consisting of IL-1F7b and IL-18BP was observed on SDS/PAGE. We propose that after binding to IL-18BP, IL-1F7b forms a complex with IL-18Rbeta, depriving the beta-chain of forming a functional receptor complex with IL-18Ralpha and thus inhibiting IL-18 activity.